BMJ open · 2026
Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology: a systematic review and meta-analysis protocol.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ostrowska Joanna, Strzebonska Karolina, Waligora Marcin
Аннотация
INTRODUCTION: Paediatric phase I oncology trials establish safe dosing and provide preliminary efficacy data for investigational anti-cancer agents in children. The aim of the proposed systematic review is to identify the risk and benefit ratio for targeted therapy agents in paediatric Phase I trials in oncology.
METHODS AND ANALYSIS: We will search Embase and PubMed for paediatric Phase I cancer trials published from 2 March 2015 to 30 June 2026. Eligible studies are dose-escalation trials enrolling participants under 21 years with solid or haematological malignancies, testing targeted therapy agents. We will measure two co-primary outcomes: (1) risk-proportion of participants experiencing drug-related adverse events of grade 3, 4 or 5; and (2) benefit-objective response rate. Where data permit, proportions will be pooled using random-effects meta-analysis.
ETHICS AND DISSEMINATION: This study will use publicly available data; therefore, ethics committee approval is not required. Results from the systematic review will be published in a peer-reviewed journal and presented at relevant conferences.
PROSPERO REGISTRATION NUMBER: CRD420261408673.
METHODS AND ANALYSIS: We will search Embase and PubMed for paediatric Phase I cancer trials published from 2 March 2015 to 30 June 2026. Eligible studies are dose-escalation trials enrolling participants under 21 years with solid or haematological malignancies, testing targeted therapy agents. We will measure two co-primary outcomes: (1) risk-proportion of participants experiencing drug-related adverse events of grade 3, 4 or 5; and (2) benefit-objective response rate. Where data permit, proportions will be pooled using random-effects meta-analysis.
ETHICS AND DISSEMINATION: This study will use publicly available data; therefore, ethics committee approval is not required. Results from the systematic review will be published in a peer-reviewed journal and presented at relevant conferences.
PROSPERO REGISTRATION NUMBER: CRD420261408673.